6 trends tracked about this subject — the full history, oldest to newest below.
Two late-stage heart-disease medicines have failed to deliver expected cardiovascular benefits despite promising biomarker improvements, raising questions about how drug developers measure success.
Novartis's pelacarsen fails to reduce cardiovascular events in the Lp(a)HORIZON trial, casting doubt on lipoprotein(a) as a drug target and AI-driven drug discovery.
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
Novartis shares decline after its cholesterol drug pelacarsen failed a critical late-stage cardiovascular trial, impacting expectations for heart disease treatments.